Understanding drug utilisation, treatment patterns, clinical outcomes, and profile of the patients receiving lutetium (177Lu) vipivotide tetraxetan for the treatment of metastatic prostate cancer: a multicountry, AI-powered registry (PULSE)

ENCePP Code of conduct

Yes

Data sources

• Data source(s), other:
  Study database based on extraction of electronic health records
• Data sources (types):
  Electronic healthcare records (EHR)

  Non-interventional study

Use of a Common Data Model (CDM)

• CDM mapping:
  Yes

CDM Mappings

Data quality specifications

• Check conformance:
  Yes
• Check completeness:
  Yes
• Check stability:
  Yes
• Check logical consistency:
  Yes

Data characterisation

• Data characterisation conducted:
  No